M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. - Wikidata - wikimedia - TriplyDB

M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.

M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.

http://www.wikidata.org/entity/Q44591611

about

The mTOR signalling pathway in human cancer In vitro and in vivo assays for osteoclast apoptosis Inflammation, bone loss and fracture risk in spondyloarthritis Role of bone-anabolic agents in the treatment of breast cancer bone metastases Effects of anti-tumor necrosis factor α agents on bone The alliance of mesenchymal stem cells, bone, and diabetes Crystal structure of human osteoclast stimulating factor Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB Regulation of osteoclast differentiation M-CSF Mediates Host Defense during Bacterial Pneumonia by Promoting the Survival of Lung and Liver Mononuclear Phagocytes.Validation of anti-aging drugs by treating age-related diseases.Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption.Saturated fatty acids enhance osteoclast survival Regulation of Embryonic and Postnatal Development by the CSF-1 Receptor.The best of both worlds - managing the cancer, saving the bone.Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency.Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in fibroblasts ERK1 regulates the hematopoietic stem cell niches Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis.Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data Cytokine-mediated bone destruction in rheumatoid arthritis.Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts The molecular pathogenesis of osteosarcoma: a review Anti-inflammatory and antiosteoclastogenic activities of parthenolide on human periodontal ligament cells in vitro.Nutrigerontology: why we need a new scientific discipline to develop diets and guidelines to reduce the risk of aging-related diseases.Association of bone loss with the upregulation of survival-related genes and concomitant downregulation of Mammalian target of rapamycin and osteoblast differentiation-related genes in the peripheral blood of late postmenopausal osteoporotic women.Pathway analysis of microRNA expression profile during murine osteoclastogenesis 5-Azacytidine-induced protein 2 (AZI2) regulates bone mass by fine-tuning osteoclast survival Erythropoietin mediated bone formation is regulated by mTOR signaling.Cancer-targeted therapies and radiopharmaceuticals Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.Cytokine expression and accelerated tooth movement.A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis.A short report: PAMM, a novel antioxidant protein, induced by oxidative stress.A new regulator of osteoclastogenesis: estrogen response element-binding protein in bone.Dysregulation of Mitochondrial Functions and Osteogenic Differentiation in Cisd2-Deficient Murine Induced Pluripotent Stem Cells Forced expression of human macrophage colony-stimulating factor in CD34+ cells promotes monocyte differentiation in vitro and in vivo but blunts osteoclastogenesis in vitro.Myeloid lineage skewing due to exacerbated NF-κB signaling facilitates osteopenia in Scurfy mice.alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology.

P2860

Q24627306-09DE2BA2-344C-49C6-8D75-3AC35B2EB36E Q24815945-74752880-E61C-4DC0-83D3-C5FCC9FBB83D Q26778258-26E556F9-205F-4B63-AC82-F80A4ACCD3AB Q26822732-3D2EEB81-FE5E-46F9-AABD-AD532EA1261D Q26851274-4D592FE1-E4BA-46CF-BC5B-B9BAA6EFD485 Q27012497-C602C1AD-445E-430D-8C31-BA415D3BAD41 Q27653392-5B389B73-E6F5-42C5-962B-EA429269BBDA Q28506372-0713810B-0778-4E7D-9ECB-013E3EF05E03 Q28593319-72943915-E2E8-4720-8262-A2F52704C9C4 Q30276802-749002B0-4634-4216-BD3E-87D26C98E935 Q33588700-6C82C0FF-B6E7-4250-B692-6965A8AA7467 Q33729192-043FFE90-B28B-4E92-89CC-BB3A0303EEA2 Q33784591-F8B78589-7951-4F5F-9EA0-4447529D8F2F Q33820660-86BF1075-7226-45D8-B11E-AD06AB99940E Q33920055-5766E3AA-E1D4-4747-9D8A-7D7CE16AC259 Q34017216-C26B8013-C67C-4CAB-BCB4-039EC9E56D9E Q34023663-04692795-DC12-4462-A931-E84CCAB6BC21 Q34070565-36B290F4-492E-46FC-B2FC-EC27177527A2 Q34150006-0271B8E6-62A3-46A1-AD58-F14D93550D21 Q34151605-194E9E09-0993-4BC5-96EF-6478672C66D3 Q34182834-E99148A1-6692-45B4-B063-81F6B0E581D4 Q34252489-97E7A931-6268-416C-B4F2-8DE7D2206FF8 Q34574959-A6F3168B-F1D4-4880-B3BE-CEAE5D85624C Q34629074-5B1631DB-9247-4D8F-A575-D864AAADA64D Q34909032-638610EA-DFAE-47F1-B323-CA372CEDA5AD Q35080563-3F705390-8868-4533-84A7-0A943FCFBB4D Q35113761-E4E5C04E-25C5-4287-9A81-539975D90D59 Q35252690-CEACEC23-2DA8-4103-81B6-4C3120717E6E Q35351495-8AFF8948-7D75-4FF6-A935-99EB1FAF76EE Q35613027-0BF15BFD-FC1D-4A9C-B43B-C46540B0FC50 Q35683440-38628F84-681A-4D80-AAF6-9088498F9B95 Q35807838-B1C8DE70-AE59-47FC-AFF2-84CD4B62B9D7 Q35866637-EDCF88D1-DD13-4926-BCE5-8CEB3CEEDD07 Q36053859-B9E68F36-2A27-43F9-9144-1805DC770A3B Q36106338-16A5C27D-9898-42F4-80BB-F429FC87F8B9 Q36160358-8D034906-7439-43AC-9610-0402A0D14C0A Q36206064-10908B38-8992-4670-B2D7-840F8C8283BB Q36270576-BBAE5EE4-555B-495E-A844-07C79A0C068F Q36293309-0BCA87EC-11AD-4CD8-BC03-17AE4EA33103 Q36324934-A357C925-415F-4FDF-989B-6F45097E0500

P2860

M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.

http://www.wikidata.org/entity/Q44591611

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

M-CSF, TNFalpha and RANK ligan ...... naling through mTOR/S6 kinase.

@en

M-CSF, TNFalpha and RANK ligan ...... naling through mTOR/S6 kinase.

@nl

type

label

M-CSF, TNFalpha and RANK ligan ...... naling through mTOR/S6 kinase.

@en

M-CSF, TNFalpha and RANK ligan ...... naling through mTOR/S6 kinase.

@nl

prefLabel

M-CSF, TNFalpha and RANK ligan ...... naling through mTOR/S6 kinase.

@en

M-CSF, TNFalpha and RANK ligan ...... naling through mTOR/S6 kinase.

@nl

P1433

Q44591611-7D309E3C-7B9C-4D05-8684-DA562A7A9530

P1476

Q44591611-A918B449-740C-4EAC-9E71-D26B1506DD7A

P2093

Q44591611-4D921D88-3935-4F29-8DB0-462169232F73

Q44591611-655E30B2-157A-4C90-A8CC-42D485BC3FCF

Q44591611-912BD5C3-1BE6-44FD-B02D-9DD4589D4914

Q44591611-A9E44C15-80FD-4064-ACFD-5C0D7B58A1C4

Q44591611-C95328BC-2AC8-4A6A-8FB4-079D0C574FCA

P2860

Q44591611-00E23BAF-B547-4A80-A05F-C361DFB88825

Q44591611-01F583AA-4FBD-4AA7-9B36-FAF30FD3DF33

Q44591611-02342990-909D-4455-B1C2-EB9459C26943

Q44591611-033AF981-A445-4B21-8864-8D4E6E5A471D

Q44591611-05151A5E-9164-44A3-97A1-2B038587AC7E

Q44591611-07C630D3-0337-4CD2-8869-D71F04434964

Q44591611-1A7AFB52-1936-4654-AB1B-A61535C0AE15

Q44591611-1BD24B75-C3B6-4FA8-9BA7-39E4CF65F369

Q44591611-2179320D-3259-4E78-AA2F-62D1886C5A55

Q44591611-2F1ECCC0-5D08-4A87-A332-C795AD88B5C2

P2888

Q44591611-7D46A4B6-6B6B-4AA1-B8E5-CC25CCE7FA4D

P304

Q44591611-517708E0-AF50-4D89-9831-8CA2D839586D

P31

Q44591611-E56D9E52-46EB-4473-B3A6-11A3D5C94294

P356

Q44591611-1F594232-35F3-4391-A6F8-5B6617C89863

P433

Q44591611-02C24AC1-265A-43B4-9AA6-0C533FD37865

P478

Q44591611-67B024A6-14B8-4AD7-92C5-205C52F1111D

P577

Q44591611-6A028860-0045-493D-A0D8-D0BCCC97734F

P5875

Q44591611-058E7C59-8206-46CE-B8EA-756037B6A7A9

P698

Q44591611-5BFC2CA3-3642-4A7A-83B8-2084BFDB78B2

P356

P1433

Cell Death & Differentiation

P1476

M-CSF, TNFalpha and RANK ligan ...... naling through mTOR/S6 kinase.

@en

P2093

A A Reszka

http://www.w3.org/2001/XMLSchema#string

G A Rodan

http://www.w3.org/2001/XMLSchema#string

G Wesolowski

http://www.w3.org/2001/XMLSchema#string

H Glantschnig

http://www.w3.org/2001/XMLSchema#string

J E Fisher

http://www.w3.org/2001/XMLSchema#string

P2860

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

Caspase cleavage of MST1 promotes nuclear translocation and chromatin condensation

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

P2888

P304

1165-1177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.CDD.4401285

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9087214

http://www.w3.org/2001/XMLSchema#string

P698

14502240

http://www.w3.org/2001/XMLSchema#string